About Vir Biotechnology
Vir Biotechnology develops treatments that leverage the immune system to combat infectious diseases. The company uses a proprietary monoclonal antibody platform combined with machine learning to create a database of human antibodies, which aids in developing effective medicines. Their pipeline includes candidates for hepatitis B, hepatitis delta, HIV, and various viruses like influenza and COVID-19. Vir stands out by collaborating with industry leaders and organizations to accelerate scientific advancements, with the goal of transforming lives through innovative therapies.
San Francisco, CaliforniaHeadquarters
2016Year Founded
$640.6MTotal Funding
IPOCompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
501-1,000Employees
Benefits
Comprehensive healthcare coverage
Employer matched 401(k)
Employee stock purchase plan
Childcare assistance
Tuition reimbursement
Risks
Leadership instability due to key executive resignations may disrupt operations.
Job cuts and facility closures indicate potential financial strain.
Struggles to diversify beyond COVID-19 antibody success may impact revenue growth.
Differentiation
Vir Biotechnology uses AI-enhanced capabilities for monoclonal antibody development.
The company focuses on immune system manipulation for targeted therapies.
Vir's pipeline includes a potential functional cure for chronic hepatitis B.
Upsides
Increased interest in AI-driven drug discovery benefits Vir's AI capabilities.
The rise of personalized medicine aligns with Vir's monoclonal antibody focus.
Global pandemic preparedness funding supports Vir's broad-spectrum antiviral therapies.
Funding
Total raised$640.64 M
Latest valuation$2.20 B
StageIPO
POST IPO EQUITY
3/31/2020$250
IPO
9/30/2019$143
$2.20 BSERIES B
12/31/2018$328
$1.64 BSERIES A
7/31/2018$66
$330.00 MLATE VC
12/31/2016$150
$750.00 M